EE05558B1 - Antikeha v?i selle antigeeni siduva fragmendi v?i lahustuva polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks - Google Patents

Antikeha v?i selle antigeeni siduva fragmendi v?i lahustuva polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks

Info

Publication number
EE05558B1
EE05558B1 EEP200100146A EEP200100146A EE05558B1 EE 05558 B1 EE05558 B1 EE 05558B1 EE P200100146 A EEP200100146 A EE P200100146A EE P200100146 A EEP200100146 A EE P200100146A EE 05558 B1 EE05558 B1 EE 05558B1
Authority
EE
Estonia
Prior art keywords
antigen
antibody
preparation
pharmaceutical composition
binding fragment
Prior art date
Application number
EEP200100146A
Other languages
English (en)
Estonian (et)
Inventor
R. Mundy Gregory
Yoneda Toshiyuki
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of EE200100146A publication Critical patent/EE200100146A/xx
Publication of EE05558B1 publication Critical patent/EE05558B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Photoreceptors In Electrophotography (AREA)
EEP200100146A 1998-09-14 1999-09-13 Antikeha v?i selle antigeeni siduva fragmendi v?i lahustuva polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks EE05558B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10018298P 1998-09-14 1998-09-14
PCT/US1999/021170 WO2000015247A2 (en) 1998-09-14 1999-09-13 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists

Publications (2)

Publication Number Publication Date
EE200100146A EE200100146A (et) 2002-06-17
EE05558B1 true EE05558B1 (et) 2012-08-15

Family

ID=22278506

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100146A EE05558B1 (et) 1998-09-14 1999-09-13 Antikeha v?i selle antigeeni siduva fragmendi v?i lahustuva polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks

Country Status (29)

Country Link
US (1) US7211252B2 (tr)
EP (2) EP2065050A1 (tr)
JP (3) JP2002524529A (tr)
KR (1) KR100628818B1 (tr)
CN (1) CN1236815C (tr)
AT (1) ATE418999T1 (tr)
AU (1) AU757873B2 (tr)
BR (1) BR9913705A (tr)
CA (1) CA2343579C (tr)
CY (1) CY1109413T1 (tr)
CZ (1) CZ302997B6 (tr)
DE (1) DE69940206D1 (tr)
DK (1) DK1113810T3 (tr)
EA (1) EA004270B1 (tr)
EE (1) EE05558B1 (tr)
ES (1) ES2319831T3 (tr)
HK (1) HK1038313A1 (tr)
HU (1) HU229038B1 (tr)
IL (2) IL141877A0 (tr)
IS (1) IS2631B (tr)
NO (2) NO327855B1 (tr)
NZ (1) NZ511062A (tr)
PL (1) PL203114B1 (tr)
PT (1) PT1113810E (tr)
SI (1) SI1113810T1 (tr)
SK (1) SK287601B6 (tr)
TR (1) TR200100734T2 (tr)
WO (1) WO2000015247A2 (tr)
ZA (1) ZA200102032B (tr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
CA2384948C (en) * 1999-09-14 2013-07-16 Biogen, Inc. Therapies for chronic renal failure using one or more integrin antagonists
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
EP1423135A4 (en) * 2001-08-06 2006-06-07 Univ California PROCESS FOR INHIBITING THE ANGIOGENESIS
MXPA06008746A (es) * 2004-02-06 2007-01-23 Elan Pharm Inc Metodos y composiciones para tratamiento de tumores y enfermedad metastatica.
WO2007092471A2 (en) * 2006-02-03 2007-08-16 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP3042668B1 (en) * 2006-06-07 2018-09-19 The Board of Trustees of the Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
CA2711256C (en) 2008-01-03 2019-01-15 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
KR101238061B1 (ko) * 2009-03-31 2013-02-27 한화케미칼 주식회사 Ｖｃａｍ－１에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물
HUE035098T2 (en) * 2010-04-16 2018-05-02 Biogen Ma Inc Anti-VLA4 Antibodies
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
AU2012277185A1 (en) * 2011-06-30 2014-02-13 Gene Techno Science Co., Ltd. Soluble integrin alpha4 mutant
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
CN103215223B (zh) * 2013-03-18 2014-10-29 中国人民解放军第四军医大学 人椎间盘髓核细胞和免疫细胞相互作用的体外模型构建方法
CN103838980A (zh) * 2014-03-27 2014-06-04 山东大学 对多发性骨髓瘤骨病治疗方法的疗效进行模拟评测的方法
CN109432398A (zh) * 2016-03-13 2019-03-08 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
WO2017205560A1 (en) * 2016-05-27 2017-11-30 Albert Einstein College Of Medicine, Inc. Methods for treating cancer by targeting vcam1 and maea
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5217870A (en) 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5260277A (en) 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
DE69309044T3 (de) 1992-01-13 2004-12-23 Biogen, Inc., Cambridge Behandlung von asthma
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1993015764A1 (en) 1992-02-12 1993-08-19 Biogen, Inc. Treatment for inflammatory bowel disease
AU689454B2 (en) 1992-11-13 1998-04-02 Board Of Regents Of The University Of Washington, The Peripheralization of hematopoietic stem cells
WO1994015958A2 (en) 1993-01-08 1994-07-21 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
DK0682529T4 (da) 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
CA2182013C (en) * 1994-01-25 2007-07-17 Mary M. Bendig Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US5885786A (en) 1996-04-19 1999-03-23 John Wayne Cancer Institute Methods for screening of substances for inhibition of multidrug resistance
ES2263178T3 (es) 1996-06-27 2006-12-01 Chugai Seiyaku Kabushiki Kaisha Remedios para mieloma para ser utilizados junto con agentes antitumorales de mostaza nitrogenada.
PL198189B1 (pl) * 1998-05-28 2008-06-30 Biogen Idec Ma (R)-N-{[4-{[(2-metylofenyloamino)-karbonylo]amino}fenylo]acetylo}-L-prolilo-3-metylo]-ß-alanina, jej zastosowanie i kompozycja farmaceutyczna ją zawierająca
US9501219B2 (en) 2012-01-25 2016-11-22 Oracle International Corporation 2D line data cursor
US9713013B2 (en) 2013-03-15 2017-07-18 Elwha Llc Protocols for providing wireless communications connectivity maps
US9400266B2 (en) 2013-03-14 2016-07-26 Rosemount Analytical Inc. Gas chromatograph with improved operation
US9104862B2 (en) 2013-04-01 2015-08-11 Uniquesoft, Llc Secure computing device using new software versions

Also Published As

Publication number Publication date
IL141877A0 (en) 2002-03-10
JP2010235620A (ja) 2010-10-21
AU6248699A (en) 2000-04-03
IL197686A0 (en) 2011-07-31
NO20011283D0 (no) 2001-03-14
ES2319831T3 (es) 2009-05-12
NO327855B1 (no) 2009-10-05
AU757873B2 (en) 2003-03-06
ATE418999T1 (de) 2009-01-15
PT1113810E (pt) 2009-03-10
HK1038313A1 (en) 2002-03-15
TR200100734T2 (tr) 2001-07-23
KR20010085793A (ko) 2001-09-07
SI1113810T1 (sl) 2009-04-30
ZA200102032B (en) 2002-11-07
KR100628818B1 (ko) 2006-09-27
PL203114B1 (pl) 2009-08-31
HUP0103630A3 (en) 2004-03-01
US7211252B2 (en) 2007-05-01
EA004270B1 (ru) 2004-02-26
CZ302997B6 (cs) 2012-02-15
NZ511062A (en) 2003-04-29
EP1113810A2 (en) 2001-07-11
EE200100146A (et) 2002-06-17
PL347128A1 (en) 2002-03-25
CZ2001916A3 (cs) 2001-08-15
NO20011244L (no) 2001-05-14
DE69940206D1 (de) 2009-02-12
NO20011244D0 (no) 2001-03-12
HUP0103630A2 (hu) 2002-01-28
IS5856A (is) 2001-02-23
WO2000015247A8 (en) 2009-12-23
CN1236815C (zh) 2006-01-18
JP2002524529A (ja) 2002-08-06
IS2631B (is) 2010-06-15
JP2013241441A (ja) 2013-12-05
DK1113810T3 (da) 2009-04-06
SK287601B6 (sk) 2011-03-04
JP5378303B2 (ja) 2013-12-25
EA200100362A1 (ru) 2001-12-24
CA2343579C (en) 2012-05-29
CY1109413T1 (el) 2014-08-13
WO2000015247A2 (en) 2000-03-23
EP2065050A1 (en) 2009-06-03
CN1321091A (zh) 2001-11-07
US20020022028A1 (en) 2002-02-21
HU229038B1 (hu) 2013-07-29
EP1113810B1 (en) 2008-12-31
SK6052001A3 (en) 2001-12-03
CA2343579A1 (en) 2000-03-23
BR9913705A (pt) 2001-06-05
WO2000015247A3 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
EE05558B1 (et) Antikeha v?i selle antigeeni siduva fragmendi v?i lahustuva polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks
ATE480252T1 (de) Peptidantagonist von zonulin und dessen verwendung
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
ATE375362T1 (de) Von cyclophilin b abstammende tumorantigen- peptide
NO971557L (no) TIE-2-ligander, fremgangsmåte ved fremstilling samt anvendelse derav
IL140622A0 (en) Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
DE60038239D1 (de) Neue klinische parameter zur bestimmung einer hämatologischen toxizität vor einer strahlenimmuntherapie
DE3750342T2 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
DE69720241D1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
ATE258062T1 (de) Verwendung von wachstumshormon freisetzenden stoffen und ihren antagonisten zur behandlung von tumoren
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
EP1080724A4 (en) COMPOSITIONS FOR REDUCING MTP ACTIVITY
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
EA200001127A1 (ru) Бактериальные феромоны и их использование
DE60022879D1 (de) Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität
DE69834057D1 (de) Echinocandinderivate, deren herstellung und deren verwendung zur bekämpfung von pilzen
WO2005025603A3 (en) Methods of using wisp antagonists
EP2236619A3 (en) BCL2L12 polypeptide activators and inhibitors
EA199801032A1 (ru) Белки zona pellucida для контрацепции
FI883765A (fi) Antikroppar mot biologiskt aktiva polypeptider och deras anvaendning vid diagnostiska foerfaranden.
DE60028682D1 (de) Wachstumhormone Inhibitoren Enthaltende pharmazeutische Zubereitungen oder ihre biologisch aktive Fragmente zur Behandlung von uterinen Myomas

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20150913